Catherine Andrieu
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Catherine Andrieu has a total of 8 co-authors. Here are the top co-authors by number of shared publications:
- Aurélie Susini
Laboratoire d'Oncogénétique, Institut Curie, Hôpital René Huguenin, 35 Rue Dailly, Saint-Cloud, F-92210, France
1 shared publication - Emmanuelle Mouret-Fourme
Public Health, Institut Curie Hôpital René Huguenin, rue Dailly 35, Saint Cloud, 92210, France
1 shared publication - Géraldine Cizeron-Clairac
Laboratoire d'Oncogénétique, Institut Curie, Hôpital René Huguenin, 35 Rue Dailly, Saint-Cloud, F-92210, France
1 shared publication - Ivan Bièche
Department of Genetics, Institut Curie, Paris, France
1 shared publication - Keltouma Driouch
Institut Curie, Hôpital René Huguenin, Laboratoire d’oncogénétique
1 shared publication - Magdalena Cizkova
Laboratory of Experimental Medicine, Institute of Molecular and Translational Medicine, Faculty of Medicine and Dentistry, Palacky University and University Hospital Olomouc, Olomouc, Czech Republic
1 shared publication
Latest Publications
- Open Access
- 13 February 2012
- Published by Springer Nature in Breast Cancer Research
- Vol. 14 (1) , R28
PIK3CAmutation impact on survival in breast cancer patients and in ERα, PR and ERBB2-based subgroups
Introduction: PIK3CA is the oncogene showing the highest frequency of gain-of-function mutations in breast cancer, but the prognostic value of PIK3CA mutation status is controversial. Methods: We investigated the prognostic significance of PIK3CA mutation status in a series of 452 patients with unilateral invasive primary breast cancer and known long-term outcome (median follow-up 10 years). Results: PIK3CA mutations were identified in 151 tumors (33.4%). The frequency of PIK3CA mutations differed markedly according to hormone receptor (estrogen receptor alpha [ERα] and progesterone receptor [PR]) and ERBB2 status, ranging from 12.5% in the triple-negative subgroup (ER-/PR-/ERBB2-) to 41.1% in the HR+/ERBB2- subgroup. PIK3CA mutation was associated with significantly longer metastasis-free survival in the overall population (P = 0.0056), and especially in the PR-positive and ERBB2-positive subgroups. In Cox multivariate regression analysis, the prognostic significance of PIK3CA mutation status persisted only in the ERBB2-positive subgroup. Conclusions: This study confirms the high prevalence of PIK3CA mutations in breast cancer. PIK3CA mutation is an emerging tumor marker which might become used in treatment-choosing process. The independent prognostic value of PIK3CA mutation status in ERBB2-positive breast cancer patients should be now confirmed in larger series of patients included in randomized prospective ERBB2-based clinical trials.
- 13 February 2012
- Published by Springer Nature in Breast Cancer Research
- Vol. 14 (1) , R28
Open AccessPIK3CAmutation impact on survival in breast cancer patients and in ERα, PR and ERBB2-based subgroups
Introduction: PIK3CA is the oncogene showing the highest frequency of gain-of-function mutations in breast cancer, but the prognostic value of PIK3CA mutation status is controversial. Methods: We investigated the prognostic significance of PIK3CA mutation status in a series of 452 patients with unilateral invasive primary breast cancer and known long-term outcome (median follow-up 10 years). Results: PIK3CA mutations were identified in 151 tumors (33.4%). The frequency of PIK3CA mutations differed markedly according to hormone receptor (estrogen receptor alpha [ERα] and progesterone receptor [PR]) and ERBB2 status, ranging from 12.5% in the triple-negative subgroup (ER-/PR-/ERBB2-) to 41.1% in the HR+/ERBB2- subgroup. PIK3CA mutation was associated with significantly longer metastasis-free survival in the overall population (P = 0.0056), and especially in the PR-positive and ERBB2-positive subgroups. In Cox multivariate regression analysis, the prognostic significance of PIK3CA mutation status persisted only in the ERBB2-positive subgroup. Conclusions: This study confirms the high prevalence of PIK3CA mutations in breast cancer. PIK3CA mutation is an emerging tumor marker which might become used in treatment-choosing process. The independent prognostic value of PIK3CA mutation status in ERBB2-positive breast cancer patients should be now confirmed in larger series of patients included in randomized prospective ERBB2-based clinical trials.